5-fluorouracil + cyclophosphamide + doxorubicin + methotrexate + prednisone + vinblastine + vincristine

This multi-drug chemotherapy regimen, consisting of 5-fluorouracil, cyclophosphamide, doxorubicin, methotrexate, prednisone, vinblastine, and vincristine, does not appear as a single established regimen in the search results. However, it comprises many drugs found in similar combination chemotherapy regimens such as CAF (cyclophosphamide, Adriamycin [doxorubicin], 5-fluorouracil) and CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone), which are used primarily in breast cancer treatment. These regimens are employed for various solid tumors. Response rates (e.g., 64% for CAF, 37% for CMFVP) and toxicity profiles (including nausea, vomiting, malaise, alopecia, granulocytopenia) vary between established combinations. Administration schedules are typically intermittent (e.g., 1 week out of 4) or according to other detailed protocols.